Prevalence of Cannabinoid Use in Patients With Hip and Knee Osteoarthritis

INTRODUCTION: State legalization and widespread marketing efforts have increased the accessibility and consumption of off-label, non–FDA-approved, cannabinoid (CBD) products. Although clinical evidence is largely absent for the treatment of musculoskeletal pain, patients are experimenting with these...

Descripción completa

Detalles Bibliográficos
Autores principales: Deckey, David G., Lara, Nina J., Gulbrandsen, Matthew T., Hassebrock, Jeffrey D., Spangehl, Mark J., Bingham, Joshua S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861619/
https://www.ncbi.nlm.nih.gov/pubmed/33986220
http://dx.doi.org/10.5435/JAAOSGlobal-D-20-00172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861619/
https://www.ncbi.nlm.nih.gov/pubmed/33986220
http://dx.doi.org/10.5435/JAAOSGlobal-D-20-00172

Ejemplares similares